Good morning, everyone. Day two of our London Healthcare Conference. Very grateful to see such great attendance and all these smiling faces despite the rainy weather, but we are in London, so it is to be expected.
My name is Akash Tewari. I head our biotech and pharma research efforts here at the firm, and I have the pleasure of hosting argenx, which has been our top pick since I think I have launched as an analyst, and certain companies make you look smarter than you are. This has been one of them. Peter and Beth, we have today. Why do I hand it over to the team for some intro remarks, and we will get started.
Yeah, I mean, I think just to get started, it has been a very productive, exciting year at argenx. We have had an amazing commercial launch. I think MG and CIDP continue to grow, and VYVGART is really changing the treatment paradigms across both of those. We had an exciting data point that came out in August with the myositis readout, the ALKIVIA readout, and what we have talked about is that we are going to be moving, filing an IMNM forward, and will be one of what could potentially be five launches next year.
So we will see a lot of growth across our commercial business next year. We set a Vision 2030 a couple of years ago, and we are making really good progress against that towards reaching 50,000 patients globally with our medicines across 10 labeled indications, and then also advancing five new assets into late-stage development.
We are seeing a lot of progress also in that early phase growth of our pipeline. We have added multiple new molecules to the pipeline this year. We will have 10 clinical phase assets in our pipeline this year, and that really sets us up for long-term growth, and I think that is what we are focused on in growing our immunology innovation business.
Understood. So I do want to start on Vision 2030 because, if you can put in an average cost of patient assumption, you can put in total number, you get a very big 2030 P&L. Maybe you are trading at 3x your current market cap. That is for me to say, not necessarily for you. But I think one of the questions I often get from investors is, how much more in terms of data readouts do they need to actually hit that target?
Or now that you actually have IMNM and you have CIDP, you have gMG, you may actually have enough indications today to feel comfortable with that target. What can you comment about, A, your confidence on that 50,000 number, but also, do you need any more indications?
Yeah, I mean, we're on track to achieve our Vision 2030. I think we're in really good shape. From the 50,000, I mean, just from a timing perspective, from the opportunity that we see with MG and CIDP to kind of continue to reach into those markets, you can imagine that the majority of that 50,000 will be from MG and CIDP.
But the expansions that will come next year, like I said, five potential launches next year, will contribute also to that 50,000. But I think we feel good about our ability to reach it. I mean, still some room to go. We'll probably give an update on how we're tracking against that Vision 2030. But yeah, I think we're in really good shape.
And can you help us, because I don't think people understand you do have five launches next year. Talk to us about some of those opportunities in terms of which ones could be probably the most material contributor to that 50,000 number?
Yeah, so what's the important opportunities next year? Two of them actually are within MG. One is the expansion into pediatric MG, and one is the expansion into ocular MG. I think what this goes to talk about is really a trend that we're seeing broadly in MG, which is that 80% of patients are still treated with a conventional therapy, whether it's a steroid, whether it's a broad immunosuppressant.
So that's really the opportunity we see here, to shift treatment of biologics earlier, and VYVGART is really driving that growth. With the seronegative label expansion, we saw continued push into earlier treatment, but also kind of an opportunity for simplicity for physicians to not have to think about antibody status. I think what's happening with the pediatric and the ocular, it's for physicians to say, "Why wait to treat with a biologic when you get the efficacy, when you get the safety that you have with a molecule like VYVGART?"
Those label expansions continue to remove those hurdles to wait. So it's not only reaching new patient populations, but it's also just shifting that mindset of physicians for biologics to be used earlier. We will also be launching an auto-injector next year. So we had the prefilled syringe that launched last year that really changed the treatment paradigm for patients, particularly in the U.S., removing the need to go into a physician office for treatment, but to being able to treat at home.
The auto-injector won't likely be a step change in that same way, but it will continue to improve and innovate on that treatment experience. And then w e will have our first approval in a rheumatology indication with VYVGART, with IMNM, and there is nothing approved in this indication. That is an important step also forward in expanding the VYVGART franchise. We are still waiting on one data point before the end of the year, which would be the fifth launch, which is in our second medicine, empasiprubart, in MMN.
Understood. Before we will get into MMN, maybe just lastly on gMG, you guys have talked about, assume kind of consistent patient adds, gMG, CIDP, out for the foreseeable future. I think if we even do that, you will get to, let us say, 40,000. You could get to a big number of your 50,000.
We are seeing, I know you do not fully disclose it, but my back-of-the-envelope math would suggest an acceleration on gMG patient adds, given that you have had multiple launches even this year, where you are getting more and more of that 60,000 TAM that you really talked about. Could we be maybe in a period where maybe this is not a long-term sustained run rate, but we are in a period of elevated patient adds with gMG as you launch these new products?
Well, I will let you make the assumptions there on patient adds.
Yeah.
I think it is fair, exactly what I was talking about is of that mindset shift of not only are we unlocking new patient populations, but there is just this shift into earlier treatment, and VYVGART is driving that. I think it is that we are transforming the treatment paradigm. We are raising expectations of what patients should expect from a treatment, and then each of these expansions does kind of unlock some of that momentum. We actually had 10% new prescribers with the seronegative launch.
They were new to VYVGART once we had the seronegative label expansion. That is not just physicians prescribing for seronegative, that is physicians also kind of being reactivated to prescribe for acetylcholine receptor positive. Again, that simplicity is changing the treatment paradigm and broadly having a halo effect across MG.
What we said last quarter was actually the third quarter was amongst our highest patient adds in a quarter. I think it is fair to say that there is a step change of what's happening in MG, and that should continue.
Understood. When we get into MMN, and this is my observation, I do not know if you have necessarily framed it this way, but I feel like the kind of binary view, superiority, non-inferiority, fail, I do not think really captures the range of outcomes here. I mean, and I know you have not disclosed your non-inferiority margin. It would be great if you did. But let us say it is grip strength improvement of four points.
Maybe that is statsig, maybe that is not. We do not know. But I cannot help but think, when I look at the relative change that IVIg would have, you are doubling it. I do not really think it matters if it is statistically significant or not. I think a doctor would say, "I am going to have at what will end up being a monthly subq. I will not have variability on grip strength like we will often see with IVIg.
Not only are these patients going to be stable, but there will be a market improvement in terms of their grip strength that I am going to see." Do you feel like maybe we should be looking at it that way, where it is like non-inferiority trends towards superiority and superiority when we think about the commercial outlook for this product?
Yeah, I think you are correct. Basically, if you look at differentiation, typically you look at three parameters: efficacy, safety, and convenience. On the convenience element, it is quite clear that empa has a superior option or is a superior option as compared to IVIg. On the safety, let us see. Then on the efficacy, I think indeed non-inferiority is the base case, gives you a new option for these patients, and then indeed superiority would be a great upside. But I think there is indeed that gray zone where numerically improvement is also definitely a win.
Hmm. Just to put a finer point on that, what would your team, based on kind of physician feedback, forget statsig or not, but what would you consider to be a numerically meaningful improvement on grip strength with empa?
Yeah, I think the number which is out there is 8 kPa . I think even if you have numerically less, that is considered a win. Yeah.
Okay. Understood. Now, a couple other points on this study that we often get asked for investors. One is really, how comfortable are you that patients who are stable on IVIg will remain stable? The sense talking to your team is you do expect, you can look at some of the GAMMAGARD precedents that IVIg shouldn't necessarily materially improve during the kind of pivotal period of this trial.
But I'd love to get your sense, what are your general assumptions on placebo or IVIg performance in this trial, and what gives you confidence that we will see stability on the IVIg arm for MMN?
Yeah, so I think what we're doing is we're recruiting active MMN patients, obviously, and we're also following a few cycles prior to randomization. So that is important as that gives you the entry point in your study. Our assumption for the randomized part is indeed that these patients will be stable in terms of grip strength, maybe a little bit improvement on grip strength, but not materially.
Okay. On dose selection, you have, I think, some competing companies who, and I do not agree with some of these questions, but it is like, "Well, what dose are you taking? You have not necessarily disclosed." But when I looked at it, you did not necessarily see in your phase II study a dose response between Cohort 2 and Cohort 3. You guys have also been really thoughtful in terms of you never want to fully knock down C2, and you have this kind of sweeper MOA.
So two parts here. One, how comfortable should investors be that you are getting significant knockdown on C2, and could you define a range that you are targeting with your go-forward trial? And number two, can you comment a bit about why we may not see the high dose that you are going forward with in your MMN phase III.
I think how we selected the dose was based on our phase II data, where indeed you had two different dosing cohorts. We also had an open label where we spread out the dosing, so that gave additional PK/PD efficacy data, and based on that, we decided our dose. I think in terms of complement inhibition, it is definitely a dose which is on the higher end of complement inhibition.
So, I know there are rumors out there that we needed to select a lower dose due to some safety events. That is nonsense, actually. So, it is on the higher end of the complement inhibition, so that should give investors confidence that we are hitting that pathway very heavily.
Okay. Very helpful. Now, maybe kind of stepping back and thinking about the MMN opportunity. This is where I know your team is going to be hosting an event for the sell side at the conference. There is, I think, desire to understand how big this market could actually be, kind of prevalence figures are all over the place. But I know your team also did a really good job with CIDP, where you are like, "Look, 48,000 patients, 24 that we might target over time, and then 12 that are not well controlled."
Help us out when we think about MMN. Who is not well controlled? So they are on IVIg, they might have a response, they might even be stable, but you do not think they are necessarily well controlled. Number two, how big is the prevalence of this based on your work?
Yeah. So maybe we will talk a little bit about the MMN patient today. The only available treatment option is IVIg, and these patients are on a high volume of IVIg. They are typically getting treatment every two to four weeks. What we see over time is actually those treatment intervals are getting shorter and shorter. So from a per-patient volume perspective, these are high users of IVIg, and it is really where we see this opportunity that we designed the trial around non-inferiority.
If we have non-inferiority, we are showing the consistent efficacy. We think what is an improved safety opportunity just without the side effects that are typically associated with IVIg and the treatment convenience. Right now, we talk about a market that is about 12,000 across our key markets.
We'll get into more details around the time of approval of what that addressable market would look like, but you can imagine just given where patients are today and what their opportunity are, that if we bring a treatment forward that is getting to the underlying driver of disease, that that's going to be a very compelling value proposition, and we should be able to get a large proportion of those patients. But it's too early to say yet. I think the data will be an important driver.
Okay. Lastly on MMN, and you've gotten this question a million times, but let's put it on the record. A, confidence that your team could hit on superiority, and comment a bit about what you've seen, at least maybe on a blinded basis to the extent you can, about site deviations, things like that. Then number two, let's say that we're thinking about superiority, non-inferiority, and then maybe even with trends. When we think about peak and then also uptake, how does that change the commercial outlook?
Maybe on the study dynamics, I think what we see is a high-quality executed study. We see very little dropouts. I think that is also an important element. I think on the opportunity, Beth, maybe you would like to comment.
Yeah. I think if you balance non-inferiority, superiority, it really doesn't change the peak. This is a market that we believe that we can enter, establish a market, and really expand and shape the market. So I think that it doesn't change the peak. It could potentially change the slope somewhat, but really, this is an opportunity that we think, similar to MG, that this is a market that is in need of new options and that will really shape over time.
Understood. Now, stepping back, this is something I know my team and I are personally excited about. We cover Spyre. We are believers in, let us say, combination therapy for kind of a lower band in price for I&I. When I kind of step back, I think you are probably one of the only teams that is really exploring combination approaches, selective combination approaches when it comes to orphan indications.
You guys have markedly not gone with cell therapy. You have not gone with immune reset approaches. We have kind of the first real card flip on that potentially next year with ADAPT-Forward.
Can you talk about your team's excitement with combining C2 and VYVGART, what you think you could see on an MG-ADL response rate, and how, let us say, if you are going to be able to get a real improvement on efficacy, what does that do for your outlook on having a replacement to VYVGART as we go into the next decade?
Yeah. First and foremost, I think we are doing a biological experiment. That is step number one. The idea is that VYVGART is a great drug, but not everybody is responding. We have the largest MG data set also translationally, and what we saw is that in these partial responders, there was still some complement activity. So that is the biological reason to combine. I think the ambition from an efficacy point of view should be high. I think we would like to see a high number of patients getting to minimal symptom expression, or at least almost there.
So I think that is step number one. We have a platform study where we can also test different combinations and pick the biological winner, so to speak. In terms of next steps, maybe, Beth, you can comment.
Yeah. So we are running the first ADAPT-Forward cohort, which is in MG patients who have, as Peter said, not fully responded to VYVGART, and I think we should have an initial data set next year on that. But we do have a full pipeline of immunology assets, and I think what you are saying is exactly right, Akash.
We want to be shifting towards patients who we can get to, say, a symptom-free status, whatever that disease is, of really elevating that efficacy bar, and we have the tools to do it. So I think you will start to see that combo becomes an approach that we use pretty broadly, and it is something that we believe will be a shift in autoimmunity.
Understood. Just to put a finer point on this, we had looked at this. Maybe half of your patients who are partial responders to VYVGART have evidence of residual complement activity. This is your own kind of work. We've looked at academic data sets for patients who were VYVGART non-responders. They get put on SOLIRIS. There's a 60% response rate there. So when I look at VYVGART, got 45% kind of complete strong responders, you've got 35% maybe who are in the middle, then the rest are non-responders.
I can't help but think you could shift those buckets rightward pretty meaningfully. You could see scenarios where, let's say, you can get an MG-ADL response with a seven or eight handle on it. I mean, am I crazy thinking that? How much of an improvement could the combination actually give you from an efficacy perspective?
Yeah, that is assuming that everything is linear, obviously. So let's wait for the biological data. I think what is also an important element is what is the safety looking like if you combine these two immunosuppressive therapies? Another question is, do you need that combination all the time? I think you can also think about a combination period then followed by monotherapy. So I think these are the degrees of freedom. Let's first look at the ADAPT data card on ADAPT-Forward and see what the next steps are.
Understood. Then, just lastly on this, if the ADAPT-Forward is in gMG, if we look at your master protocol, you have a combination approach for CIDP, you have combinations with your MuSK antibody. It sounds like you might be able to go into pivotal studies on this relatively quickly. So, let's say that we get the ADAPT-Forward card flip next year. How soon could we see a combination phase III trial in gMG for argenx? Comment maybe a bit on that same path forward with CIDP.
Yeah, maybe I think we would not stop if we see spectacular data on the first combo. That's maybe giving you the answer to the first one. I think the future in autoimmunity will be combo, so I think we're definitely looking into initiating that combo in other indications. For CIDP, let's maybe wait first to demonstrate that C2, that empasiprubart, can do something, then think about what is still left from a patient's unmet needs, then see what a combination approach could look like in that disease.
Okay, understood. Now going also into your next-gen pipeline, you have several next-gen FcRn approaches as well, two long-actings, and then an oral that you seem to be increasingly excited about. We saw a BD deal there internally with your team as well. Let's talk maybe on the two long-actings. It does seem like you want to move both forward, but maybe at different pricing bands, because there are a lot of different ways that FcRn can go. If we think about the longer-acting potential one, because I know you have ARGX-124.
And then ARGX-213. One, how much of a focus is for your team to not have an on-body infusion with a longer-acting FcRn? I know you guys recently expanded your partnership with Halozyme. Number two, when we think about where dosing could ultimately head to, I mean, could we get to quarterly dosing dynamics?
Yeah, I mean, if you start with the goal here is we've really pioneered the FcRn class, and we want to be leaders in the FcRn class for the decades to come. There's a lot of opportunity within it, and we're going to continue, along with our FcRn peers, to unravel what that full opportunity could look like. That's where it starts. VYVGART LOE will come at some point, so making sure that we do have this long-term strategy. ARGX-213 is what we would hope would be monthly dosing.
We haven't talked too much about ARGX-124, but I think what you get with two is that we can start to make different choices of, do you move your current business to one? Do you start to think about orphan and larger indications? Do you think about neurology, rheumatology?
We haven't talked fully about this, but this is a topic that we're going to spend more time on next year, because I think it's really important to understand really what this long-term FcRn strategy looks like.
Hmm. Understood. Now, going into the Forte acquisition, my team, we've really struggled. There's differences in gluten challenge, there's differences in placebo response. I do think the Teva program looks competitive. There's no doubt about it. But your team has said, "Our data sets, we feel very confident, are very competitive." But I want to put a finer point on that. So, when your team looks at the data so far, and of course you have a better sense of what an apples-to-apples comparison is, you do have a slightly different MOA right here.
Do you feel confident that you can deliver similar efficacy to what we've seen out of Teva? Or is there a view internally actually that you could have superior efficacy, because you're actually impacting the biology in a different way?
A lot of questions in one question. I think on what we know is that IL-15 is definitely involved. I think what we have is also a robust data set with CD122. The real question is blocking also that IL-2 arm giving you efficacy benefits? I think it's a bit too early to tell that. Then you really need to do an apples-to-apples comparison in a pivotal trial. An important element will be also symptomology. I think what we see is from day one of gluten challenge, a difference in symptoms, active versus placebo.
On the IL-15, the data is still out there, is not really public. So I think that might be a differentiating factor on the very first gluten challenge. On the long term, I think there is a potential that the CD122 has more remission option as compared to the IL-15.
Interesting. Okay.
TBD, because I think the exposure up to date is only three months, so let's see what longer exposure gives.
Understood. Now, it's interesting, when I catch up with your team, again, we've seen now an increased cadence of external BD, but still very pragmatic, fits into kind of the areas in which you want to expand into. When Sjögren's failed, I remember your team said, "We're not done, and we're looking at internal and we're looking at external candidates." You say external candidates a fair amount now when we talk.
To the extent you can comment, what do you feel like you learned with the failure of VYVGART in Sjögren's, and also some of the emerging datasets we're seeing across the space? When we think about external innovation and the types of deals you guys would explore, I mean, there seems to be kind of a hard limit in terms of how large of a transaction your team's willing to do.
Is that maybe naive perception? Is there an ability to be more aggressive here to get an asset you feel very excited about that maybe was larger than Forte? Or we have kind of a hard range here and we're not going to necessarily go beyond that?
Maybe first on the biology, I think we have probably the largest Sjögren's dataset out there. The data is still. We're finishing off the study. That will give us a lot of data, also translational data, to see which pathways are moving or not moving. That will be quite instrumental to define what is the next step.
Also from a biology point of view, you're indicating there is external data out there recently, which will help, of course, in determining what the next step should be. In terms of deal size, I think there, but that should commence, the answer is we will be disciplined.
Yeah, I mean, we've talked a lot about our capital allocation strategies. First really is building out global reach of our patients today with VYVGART, and then looking to kind of expand our pipeline into multiple pillars of growth. So we have FcRn today, but what are those pillars of growth going to be that kind of get us to 2035 and beyond? And then beyond that, really looking more at external opportunities, whether it's through our IIP or BD. I mean, we're building our future, so it will be part of our future.
I don't think we want to talk specifically about deal size, but exactly as Peter said, we'll be disciplined. I think on your point earlier, I mean, it's biology that sets the pace, science that sets the pace, and we want to invest in innovation that's going to lead to growth.
Understood. Last question before we get you out. I think Karen's done an excellent job as she's come in and really put her stamp on the company. This is at least my sense, is that she's very much, "Here's a wall, we're going to run through it." Setting clear goals internally within the company from a commercial perspective is a huge priority for her.
I would think communicating them externally is also probably top of mind for her. You keep saying now not just Vision 2030, but really Vision 2035. How close are we to getting a Vision 2035 communicated to the street?
Well, it's 2026, so we do have a couple of years to deliver on Vision 2030. I think you want to give us a little time there. You can trust that we're thinking long term. I mean, we have big ambitions. I think that's a good sentiment. I like that visual of running through walls. What we want to do is ensure that we're giving you the information, the metrics, that vision, so you also see that ambition alongside us of what it will be to be a global immunology leader for the long term.
Understood.
Stay tuned.
Got it. Hey, thank you so much. I really do appreciate it.